Drugs / GSK2292767
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03045887 | Feb → Aug 2017 | asthma | GlaxoSmithKline | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GSK2292767 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03045887 ↗ |
| Route | Inhaled | “as powder for inhalation” NCT03045887 ↗ |